CollPlant Biotechnologies (CLGN) Equity Ratio (2017 - 2026)

CollPlant Biotechnologies has reported Equity Ratio for 10 years, with the latest figure at 0.53 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 99.93% year-over-year to 0.53; the trailing twelve-month figure through Mar 2026 stood at 0.53 (down 99.93% YoY), and the FY2025 full-year result was 0.56, down 21.65% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.53, down from 0.56 in the prior quarter.
• The five-year high for Equity Ratio was 862.61 in Q3 2023, with the low at 0.53 in Q1 2026.
• Historically, Equity Ratio has averaged 185.53 across 5 years, with a median of 0.85 in 2022.
• Annual changes were most pronounced in 2023 — Equity Ratio soared 97609.43% — and 2026, when it tumbled 99.93%.
• CollPlant Biotechnologies' Equity Ratio stood at 0.85 in 2022, then declined by 2.84% to 0.83 in 2023, then decreased by 13.34% to 0.72 in 2024, then slipped by 21.65% to 0.56 in 2025, then declined by 5.63% to 0.53 in 2026.
• The last three Equity Ratio figures came in at 0.53 (Q1 2026), 0.56 (Q4 2025), and 0.66 (Q3 2025), per Business Quant data.